A Cambridge-based biotech company called Apnimed just filed paperwork to go public. The goal is to raise up to $160 million by selling shares on the Nasdaq under the ticker APMD.
Among the underwriters are Cantor Fitzgerald, Bank of America Corp., Evercore Inc., and LifeSci Capital. Apnimed intends to list its stock on the Nasdaq Global Market with the ticker APMD.
Apnimed has filed a new drug application with the U.S. Food and Drug Administration for Oxnimbi, an oral tablet intended to treat obstructive sleep apnea. The FDA now has up to ten months to make a decision following the April submission of the application by Apnimed.
Get the market news that matters in a five-minute read with Market Briefs, our free daily newsletter
"We believe Oxnimbi could be a game-changer for patients who prefer a simple daily pill over cumbersome devices," said a company spokesperson. Should the FDA grant approval, Oxnimbi would compete with Eli Lilly's Zepbound, making them the only two drug treatments for sleep apnea. Apnimed is backed by Japan's Shionogi & Co. Other investors include Morningside Ventures, Alpha Wave Global (an alternative asset manager), and Columbia Management, which is part of Ameriprise Financial Inc.
The IPO arrives after a particularly active first half of the year for pharmaceutical stock offerings in the U.S. market. According to data compiled by Bloomberg, newly public biotech and pharmaceutical companies have raised over $5 billion in 2026 to date. This compares with just $969.2 million raised during the same stretch last year.
For the comparable quarter a year earlier, Apnimed posted revenue of $3.1 million and a net loss of $28.6 million. The dramatic improvement in the latest quarter was largely driven by milestone payments from its partner Shionogi, reflecting the value of the Oxnimbi program.
The FDA's upcoming decision on Oxnimbi will be crucial for the millions of sleep apnea patients who currently rely on CPAP machines - devices that many find uncomfortable and struggle to use consistently. If approved, Apnimed's once-daily pill could offer a convenient alternative, potentially capturing a significant share of the treatment market.
For investors, the IPO is a chance to get in early on a late-stage drug candidate with a known regulatory timeline. The risk is clear: the FDA could say no, or Eli Lilly's existing treatment could stay dominant. But the biotech IPO market is clearly active for these kinds of bets right now.
The bottom line: Apnimed is a company with revenue, a drug in front of regulators, and a set of experienced backers. Whether that adds up to a good investment depends on how you feel about the risks and the timing. But for anyone watching the biotech space, this is one to keep an eye on.
Join Market Briefs, our free daily newsletter, for a quick daily rundown of the markets
